Dermatology pipeline review notes high risk of failure, large number of me-too products

A new report looking at global clinical development in dermatology has found that 42% of the pipeline in this therapy area is in the preclinical stage, 14% in the discovery phase and only 3% in pre-registration.

The report from market intelligence firm GBI Research, which looks at 850 products with a disclosed stage of development, finds also that the late stages of the pipeline are dominated by generics and biosimilars.

Associate analyst Ross Wilkinson said: “The strong presence of biologics in the late-stage pipeline could have a considerable impact on treatment algorithms in the dermatology therapy area over the forecast period.”